References
- Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P, Padmanabhan A. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol 2018;5(5):e220–e231. e220-e231. doi:https://doi.org/10.1016/S2352-3026(18)30046-2.
- Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006;107(6):2346–2353. doi:https://doi.org/10.1182/blood-2005-08-3122.
- Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72(3):925–930. doi:https://doi.org/10.1182/blood.V72.3.925.bloodjournal723925.
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344(17):1286–1292. doi:https://doi.org/10.1056/NEJM200104263441704.
- Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017;15(11):2099–2114.
- Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121(7):632–636. doi:https://doi.org/10.1016/j.amjmed.2008.03.012.
- Okata T, Miyata S, Miyashita F, Maeda T, Toyoda K. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: atypical clinical features with heparin-dependent platelet activating antibodies. Platelets 2015;26(6):602–607. doi:https://doi.org/10.3109/09537104.2014.979338.
- Perrin J, Barraud D, Toussaint-Hacquard M, Bollaert PE, Lecompte T. Rapid onset heparin-induced thrombocytopenia (HIT) without history of heparin exposure: a new case of so-called ‘spontaneous’ HIT. Thromb Haemost 2012;107(4):795–797.
- Greinacher A. Me or not me? The danger of spontaneity. Blood 2014;123(23):3536–3538. doi:https://doi.org/10.1182/blood-2014-04-566836.
- Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT? J Thromb Haemost 2008;6(9):1598–1600.
- Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W, McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost 2013;109(4):669–675.
- Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous’ HIT. J Thromb Haemost 2009;7(3):499–501. doi:https://doi.org/10.1111/j.1538-7836.2008.03263.x.
- Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med 2015;372(5):492–494. doi:https://doi.org/10.1056/NEJMc1414161.
- Elshoury A, Khedr M, Abousayed MM, Mehdi S. Spontaneous heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages and pulmonary embolism after total knee arthroplasty. Arthroplast Today 2015;1(3):69–71. doi:https://doi.org/10.1016/j.artd.2015.07.003.
- Mallik A, Carlson KB, DeSancho MT. A patient with ‘spontaneous’ heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis 2011;22(1):73–75.
- Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014;123(23):3651–3654. doi:https://doi.org/10.1182/blood-2014-01-549741.
- Baker K, Lim MY. Spontaneous Heparin-Induced Thrombocytopenia and Venous Thromboembolism following Total Knee Arthroplasty. Case Rep Hematol 2017;2017:4918623.
- Poudel DR, Ghimire S, Dhital R, Forman DA, Warkentin TE. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Platelets 2017;28(6):614–620. doi:https://doi.org/10.1080/09537104.2017.1366973.
- Irani M, Siegal E, Jella A, Aster R, Padmanabhan A. Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia. Transfusion 2019;59(3):931–934. doi:https://doi.org/10.1111/trf.15105.
- Mohanty E, Nazir S, Sheppard JI, Forman DA, Warkentin TE. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. J Thromb Haemost 2019;17(5):841–844. doi:https://doi.org/10.1111/jth.14411.
- Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest 2017;152(3):478–485. doi:https://doi.org/10.1016/j.chest.2017.03.050.
- Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood 2018;132(12):1345–1349. doi:https://doi.org/10.1182/blood-2018-04-847483.
- Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL((R)) HIT-Ab(PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res 2017;153:108–117. doi:https://doi.org/10.1016/j.thromres.2017.03.010.
- Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol 2019;12(8):685–698. doi:https://doi.org/10.1080/17474086.2019.1636645.
- Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. London: CRC Press; 2012. p. 36-88.
- Moores G, Warkentin TE, Farooqi MAM, Jevtic SD, Zeller MP, Perera KS. Spontaneous heparin-induced thrombocytopenia presenting as cerebral venous sinus thrombosis. Neurology: Clinical Practice 2020. doi:https://doi.org/10.1212/CPJ.0000000000000805.
- Bito S, Miyata S, Migita K, Nakamura M, Shinohara K, Sato T, Tonai T, Shimizu M, Shibata Y, Kishi K, et al. Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery. Blood 2016;127(8):1036–1043. doi:https://doi.org/10.1182/blood-2015-06-651620.
- Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010;8(3):504–512. doi:https://doi.org/10.1111/j.1538-7836.2009.03735.x.
- Ahmad S, Haas S, Hoppensteadt DA, Lietz H, Reid U, Bender N, Messmore HL, Misselwitz F, Bacher P, Gaikwad BS, et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res 2002;108(1):49–55. doi:https://doi.org/10.1016/S0049-3848(02)00397-3.
- Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost 2017;1(1):134–137. doi:https://doi.org/10.1002/rth2.12009.
- James J, Shiji PV, Radhakrishnan C. Cerebral Venous Thrombosis after Intravenous Immunoglobulin Therapy in Immune Thrombocytopenic Purpura. Indian J Crit Care Med 2017;21(12):869–871. doi:https://doi.org/10.4103/ijccm.IJCCM_308_17.
- Evangelou N, Littlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003;56(4):308–309. doi:https://doi.org/10.1136/jcp.56.4.308.
- Warkentin TE, Anderson JA. How I treat patients with a history of heparin-induced thrombocytopenia. Blood 2016;128(3):348–359. doi:https://doi.org/10.1182/blood-2016-01-635003.